Arecor Therapeutics plc

Arecor Therapeutics plc
(“Arecor” or the “Group”)


  • Channeling for the future revenue generate collaborations in partnership is strong with other offers anticipated in H2 and beyond

  • Key data for ultra-fast action insulin AT247 expected in H2, next step in the demonstration his potential to facilitate a fully closed-loop artificial pancreas, a transformational treatment option for people living with diabetes

Cambridge, United KingdomJuly 14, 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today provides a business update and announces its results for the six months ended June 30, 2022 will be published during the week beginning September 5, 2022.

Arecor is pleased to report progress in line with expectations, as the Group continues to advance a commerce-driven business model, advancing its best-in-class proprietary pipeline and expanding its partner portfolio. The Group’s unaudited cash position at 30 June 2022 was £13.7 million.

The pipeline of future revenue-generating collaborations is strong with further deals expected in the second half and beyond. In June, Arecor signed an exclusive formulation study collaboration with one of the world’s top five pharmaceutical companies. Here, Arecor applies the ArestatMT technology to develop improved, stable, high-concentration liquid formulations of the partner company’s proprietary products. This technology partnership continues to validate the strength and necessity of the ArestatMT technology platform and Arecor continues to build a strong pipeline of potential future collaborations.

Within the Arecor diabetes franchise, excellent clinical progress continues. In May, the Group presented positive data at the 15th International Meeting on Advanced Technologies and Therapeutics in Diabetes (ATTD) of the Phase I clinical trial of ultra-rapid and ultra-concentrated insulin Arecor, the AT278. The data, which had exceeded expectations, was well received at the international congress and supports both the continued development of the candidate and its potential to significantly improve outcomes and quality of life for the growing population of people with dementia. diabetes who have high daily insulin requirements, particularly those with type 2 diabetes. Diabetes Care,” brought together four world-class experts in the field of diabetes care to discuss the clinical data of AT278 as well as the clear clinical and patient need. Another clinical trial of AT278, in people with type 2 diabetes, is expected to begin administering patients later this year. The Group is also on track to release key data later in 2022 from the ongoing US Phase I trial investigating the potential of AT247, Arecor’s ultra-rapid acting insulin product candidate, when administered by continuous subcutaneous infusion via an insulin pump. These data are essential, both as an important next step in determining whether AT247 can facilitate a fully closed-loop artificial pancreas, a transformational treatment option for people with diabetes, and in turn, generate a package of partnership demonstrating the superiority of AT247 over the gold standard insulins available to patients today.

Sarah Howel, Managing Director at Arecor, said: We keep building strong momentum in the advancement of our internal portfolio of the best owner some products and partnership programs. This progress gives us confidence in Arecor science and business model, who buttresss our vision of transform patient care and our ambition to build great self-sufficiency biopharmaceutical company. We look forward to further progress in 2022 in our diabetesranchise, with key data for AT247 at S2 having the potential to be a significant influenceXionic point for the Band, and we continue discussions with potential the partners at expand our portfolio of revenue-generating partnership agreements. »

This announcement contains inside information within the meaning of Article 7 of Regulation (EU) 596/2014 (MAR)


For more information please contact:

Arecor Therapeutics plc

Dr. Sarah Howell, Executive Director

Tel: +44 (0) 1223 426060

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (corporate finance)
Rupert Dearden (corporate brokerage)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Notes to Editors

About Acor
Arecor Therapeutics plc is a global biopharmaceutical group that transforms patient care by bringing innovative medicines to market through the improvement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an in-house portfolio of proprietary products in diabetes and other indications, and working with leading pharmaceutical and biotechnology companies to deliver improved formulations of their therapeutic products. The Arestat™ platform is backed by an extensive patent portfolio.

For more details, please see our website,


Comments are closed.